{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:02:30Z","timestamp":1792112550329,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.autrev.2024.103686","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T18:00:33Z","timestamp":1731002433000},"page":"103686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The evaluation of type I interferon score in dermatomyositis, a systematic review and a meta-analysis"],"prefix":"10.1016","volume":"23","author":[{"given":"Chiara","family":"Castellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Scotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Navarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cavagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.autrev.2024.103686_bb0005","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2024.103686_bb0010","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0889-857X(02)00021-2","article-title":"Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria","volume":"28","author":"Mastaglia","year":"2002","journal-title":"Rheum Dis Clin N Am"},{"issue":"1","key":"10.1016\/j.autrev.2024.103686_bb0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"20","author":"Lu","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103686_bb0020","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2024.103686_bb0025","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12016-020-08822-5","article-title":"Interstitial lung disease in anti-MDA5 positive dermatomyositis","volume":"60","author":"Wu","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103686_bb0030","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103686_bb0035","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/BOR.0b013e32825a6a57","article-title":"Pathogenesis of myositis in children","volume":"19","author":"Griffin","year":"2007","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103686_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun"},{"issue":"1","key":"10.1016\/j.autrev.2024.103686_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.autrev.2024.103686_bb0050","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthrit Rheumatol (Hoboken, NJ)"},{"issue":"5","key":"10.1016\/j.autrev.2024.103686_bb0055","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/art.22558","article-title":"Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis","volume":"56","author":"L\u00f3pez de Padilla","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103686_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.833114","article-title":"Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on type I interferon system","volume":"8","author":"Hu","year":"2022","journal-title":"Front Med"},{"issue":"10","key":"10.1016\/j.autrev.2024.103686_bb0065","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/art.42526","article-title":"The type I interferon signature reflects multiple phenotypic and activity measures in dermatomyositis","volume":"75","author":"Tabata","year":"2023","journal-title":"Arthritis & Rheumatol (Hoboken, NJ)"},{"issue":"1","key":"10.1016\/j.autrev.2024.103686_bb0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2018.08.003","article-title":"Guidelines for biomarkers in autoimmune rheumatic diseases \u2013 evidence based analysis","volume":"18","author":"Giacomelli","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2024.103686_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.autrev.2024.103686_bb0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12874-015-0055-5","article-title":"Simulation-based estimation of mean and standard deviation for meta-analysis via approximate Bayesian computation (ABC)","volume":"15","author":"Kwon","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"27","key":"10.1016\/j.autrev.2024.103686_bb0085","article-title":"Evaluating non-randomised intervention studies","volume":"7","author":"Deeks","year":"2003","journal-title":"Health Technol Assess (Winchester, Engl)"},{"issue":"10","key":"10.1016\/j.autrev.2024.103686_bb0090","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.autrev.2024.103686_bb0095","series-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"issue":"1","key":"10.1016\/j.autrev.2024.103686_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/jrsm.1042","article-title":"Generalization of trim and fill for application in meta-regression","volume":"3","author":"Weinhandl","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.autrev.2024.103686_bb0105","series-title":"An Interferon Signature in the Peripheral Blood of Dermatomyositis Patients is Associated with Disease Activity Molecular Medicine (Cambridge, Mass.)","first-page":"59","volume":"13(1-2)","author":"Baechler","year":"2007"},{"key":"10.1016\/j.autrev.2024.103686_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1151695","article-title":"Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients","volume":"14","author":"Qian","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103686_bb0115","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ajpath.2015.11.010","article-title":"Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression","volume":"186","author":"Allenbach","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2024.103686_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102311","article-title":"Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications","volume":"104","author":"Xourgia","year":"2019","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.autrev.2024.103686_bb0125","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrrheum.2013.14","article-title":"Mechanistic biomarkers for clinical decision making in rheumatic diseases","volume":"9","author":"Robinson","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103686_bb0130","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1474-4422(13)70258-8","article-title":"Assessment of interferon-related biomarkers in Aicardi-Gouti\u00e8res syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study","volume":"12","author":"Rice","year":"2013","journal-title":"Lancet Neurol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T03:13:57Z","timestamp":1732677237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224001770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1568997224001770"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103686","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evaluation of type I interferon score in dermatomyositis, a systematic review and a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103686","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103686"}}